Westminster Health Forum

The future of biosimilars in the UK: regulation, access and medicines optimisation

Morning, Thursday, 8th June 2017

Central London


This seminar will provide the opportunity to discuss the future of biosimilar medicines in the UK. Delegates will assess the next steps for regulation and pharmacovigilance, the impact of increased competition between originator and biosimilar manufacturers and the challenges for embedding use in service delivery following the publication of NHS England’s What is a biosimilar medicine? guide. Sessions will also focus on the implications of the UK vote to leave the European Union on access to biosimilars, key issues for clinicians around switching from originator to biosimilar - and the next steps for patient engagement, education and involvement.






Guest of Honour

Dr Christian Schneider

Director, National Institute for Biological Standards and Control, MHRA

Keynote Speaker

Jonathan Underhill

Medicines Clinical Adviser, Medicines and Prescribing Programme, NICE


Dr James Rose

Clinical Innovation Adoption Manager, Oxford Academic Health Science Network

Professor Jayne Lawrence

Chief Scientist, Royal Pharmaceutical Society and Professor of Biophysical Pharmaceutics, King’s College London

Helen Terry

Director of Policy, Public Affairs and Research, Crohn's and Colitis UK

Natasha Pearman

Managing Associate, Mishcon de Reya

Tim de Gavre

Chair, British Biosimilars Association and Business Unit Head, Sandoz

Ivan Blanarik

Senior Vice President and Head of Therapeutic Area, Biosimilars, Boehringer Ingelheim

Julie Wood

Chief Executive, NHS Clinical Commissioners

Dr Virginia Acha

Executive Director, Research, Medical & Innovation, ABPI